Trial Profile

First-in-man clinical study of SCMod1 [Modi-1 / AMPLIVANT combination] for cancer

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 20 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Modi-1 (Primary) ; Antineoplastics
Indications Breast cancer; Endometrial cancer; Head and neck cancer; Osteosarcoma; Ovarian cancer; Renal cancer; Sarcoma; Solid tumours; Triple negative breast cancer
Focus Adverse reactions; First in man

14 Apr 2022 Status changed from planning to recruiting, according to an ISA Pharmaceuticals media release.
10 May 2019 According to a Scancell media release, the company expects to initiate this study in Q1 2020.
10 May 2019 According to a Scancell media release, the company has appointed six world-leading clinicians to establish a Clinical Advisory Board (CAB) which will guidance and support Moditope, to enter into clinic in multiple tumour types, including head and neck, breast and ovarian cancer.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com